查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790226

帕金森氏症血液生物標記市場規模、佔有率和趨勢分析報告：按生物標記、技術、最終用途、地區和細分市場預測，2025-2033 年

Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

帕金森氏症血液生物標記市場概述

2024 年，帕金森氏症血液生物標記的全球市場規模估計為 1.1779 億美元，預計到 2033 年將達到 3.5087 億美元，2025 年至 2033 年的複合年成長率為 19.25%。由於全球帕金森氏症患者病率上升、神經診斷和生物標記研究投入增加以及蛋白質組學和基因組學技術的進步等因素，市場正在經歷顯著成長。

根據 2021 年全球疾病負擔調查的數據，研究人員預測，到 2050 年，全球將有約 2,520 萬人患有帕金森氏症，無論年齡或性別，與 2021 年記錄的數字相比成長 112%。全球帕金森氏症 (PD) 在老年人中的盛行率呈上升趨勢，尤其是在北美、歐洲和亞太部分地區。 PD 的盛行率隨著老齡化的成長而顯著增加，老齡化是該疾病的主要危險因素，尤其是對於 65 歲及以上的人。多項研究一致表明，在所有年齡層中，男性比女性更容易患有 PD。 PD 盛行率的增加與全球人口老化密切相關，這表明人口結構變化將在未來幾十年繼續增加患者數量。隨著預期壽命的增加，PD 的負擔預計會增加。 IHME 全球疾病負擔（2024 年）顯示了各大洲的 PD 病例。

患者數量的不斷成長迫切需要早期、準確且微創的診斷工具。血液生物標記為傳統臨床和影像診斷提供了相當前景的替代方案。隨著全球對神經退化性疾病的認知不斷提高，對便捷診斷的需求也日益成長，這使得血液生物標記成為應對帕金森氏症日益加重的負擔並支持早期治療性介入的關鍵解決方案。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章：帕金森氏症血液生物標記市場的趨勢和展望

  • 市場體系展望
    • 母市場
    • 子公司市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 帕金森氏症血液生物標記市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 法律規範
    • 定價分析
    • 贖回情景
    • 技術進步

第4章帕金森氏症市場中的血液生物標記：生物標記的估計和趨勢分析

  • 細分儀表板
  • 帕金森氏症血液生物標記市場：生物標記變異分析
  • 帕金森氏症血液生物標記市場規模及趨勢分析（按生物標記，2021-2033 年）
  • 蛋白質生物標記
  • 發炎標記物
  • 代謝標記物
  • 轉錄組學/miRNA
  • 其他

5. 帕金森氏症血液生物標記市場（按動物類型分類）、估值和趨勢分析

  • 細分儀表板
  • 帕金森氏症血液生物標記市場：動物類型變異分析
  • 帕金森氏症血液生物標記市場規模及趨勢分析（依動物類型，2021-2033）
  • 狗
  • 貓
  • 馬
  • 其他

6. 帕金森氏症血液生物標記市場（按技術、估值和趨勢分析）

  • 細分儀表板
  • 帕金森氏症血液生物標記市場：技術波動分析
  • 帕金森氏症血液生物標記市場規模及趨勢分析（依技術分類）（2021-2033）
  • ELISA/免疫檢測
  • 復用平台
  • NGS/qPCR（遺傳學）
  • 質譜法
  • 其他

7. 帕金森氏症血液生物標記市場（按最終用途、估值和趨勢分析）

  • 細分儀表板
  • 帕金森氏症血液生物標記市場：最終用途變異分析
  • 帕金森氏症血液生物標記市場規模及趨勢分析（按最終用途），2021-2033 年
    • 學術實驗室
    • 製藥/生物技術
    • 醫院
    • 臨床診斷實驗室
    • 其他

8. 帕金森氏症血液生物標記市場：區域、估值和趨勢分析

  • 區域儀表板
  • 2024 年及 2033 年帕金森氏症血液生物標記市場佔有率
  • 區域展望
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 公司簡介
    • IDEXX Laboratories, Inc.
    • Abbott Laboratories
    • ACOBIOM
    • Alseres Pharmaceuticals
    • Banyan Biomarkers
    • Bio-Rad Laboratories
    • DiaGenic ASA
    • Johnson & Johnson
    • Merck KGaA
    • QIAGEN
  • 戰略地圖
    • 合併與收購
    • 夥伴關係和合作
    • 產品發布
    • 其他
  • 其他主要參與企業名單
Product Code: GVR-4-68040-667-9

Blood-based Biomarker For Parkinson's Disease Market Summary

The global blood-based biomarker for Parkinson's disease market size was estimated at USD 117.79 million in 2024 and is projected to reach USD 350.87 million by 2033, growing at a CAGR of 19.25% from 2025 to 2033. The market is exhibiting significant growth driven by rising prevalence of Parkinson's disease worldwide, increasing investment in neurology diagnostics and biomarker research and advances in proteomics and genomic technologies.

The data from the global burden of disease study 2021, researchers project that by 2050, Parkinson's disease will affect approximately 25.2 million people worldwide across all ages and sexes, an increase of 112% compared to the numbers recorded in 2021. The global incidence of Parkinson's disease (PD) is increasing due to geriatric populations, particularly in North America, Europe, and parts of Asia-Pacific. Parkinson's disease (PD) incidence rates increase significantly with age, particularly among individuals aged 65 and older, making age the primary risk factor for the condition. Some studies consistently show that PD is more prevalent in males than females across all age groups. The rising incidence of PD closely correlates with the expanding aging population worldwide, suggesting that demographic shifts will continue to drive up the number of cases in the coming decades. As life expectancy increases, the burden of Parkinson's disease is expected to grow. The graph below depicts cases of Parkinson's disease in various continents according to the IHME Global Burden of Disease (2024):

This growing patient pool drives urgent demand for early, accurate and minimally invasive diagnostic tools. Blood-based biomarkers offer a promising alternative to traditional clinical and imaging-based diagnosis, which often detects PD only in later stages. As awareness of neurodegenerative diseases increases globally, so does the need for accessible diagnostics, positioning blood-based biomarkers as a critical solution to meet the rising burden of Parkinson's and support earlier therapeutic intervention.

Blood-based Biomarker For Parkinson's Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the blood-based biomarker for Parkinson's disease market report based on technology, biomarker, end use, and region:

  • Biomarker Outlook (Revenue, USD Million, 2021-2033)
  • Protein biomarkers
  • Inflammatory markers
  • Metabolic markers
  • Transcriptomic/miRNA
  • Others
  • Technology Outlook (Revenue, USD Million, 2021-2033)
  • ELISA/Immunoassay
  • Multiplex platforms
  • NGS/qPCR (genetic)
  • Mass spectrometry
  • Others
  • End Use Outlook (Revenue, USD Million, 2021-2033)
  • Academic/Research Labs
  • Pharmaceutical / Biotech (for Clinical Trials)
  • Hospitals
  • Clinical Diagnostic Labs
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Parkinson's Disease Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of Parkinson's disease worldwide
      • 3.2.1.2. Increasing investment in neurology diagnostics and biomarker research
      • 3.2.1.3. Advances in proteomics and genomic technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Costs and Technical Complexity Restrict Accessibility in Low-Resource Settings
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Blood-based Biomarker For Parkinson's Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Reimbursement Scenario
    • 3.3.6. Technological Advancements

Chapter 4. Blood-based Biomarker for Parkinson's Disease Market: Biomarker Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blood-based Biomarker For Parkinson's Disease Market: Biomarker Movement Analysis
  • 4.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by Biomarker, 2021 to 2033 (USD Million)
  • 4.4. Protein biomarkers
    • 4.4.1. Protein biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inflammatory markers
    • 4.5.1. Inflammatory markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Metabolic markers
    • 4.6.1. Metabolic markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transcriptomic/miRNA
    • 4.7.1. Transcriptomic/miRNA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker For Parkinson's Disease Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Blood-based Biomarker For Parkinson's Disease Market: Animal type Movement Analysis
  • 5.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
  • 5.4. Dogs
    • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cats
    • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Horses
    • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Parkinson's Disease Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Blood-based Biomarker for Parkinson's Disease Market: Technology Movement Analysis
  • 6.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 6.4. ELISA/Immunoassay
    • 6.4.1. ELISA/Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Multiplex platforms
    • 6.5.1. Multiplex platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. NGS/qPCR (genetic)
    • 6.6.1. NGS/qPCR (genetic) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Mass spectrometry
    • 6.7.1. Mass spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Parkinson's Disease Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Blood-based Biomarker for Parkinson's Disease Market: By End Use Movement Analysis
  • 7.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Academic/Research Labs
      • 7.3.1.1. Academic/Research Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Pharmaceutical / Biotech
      • 7.3.2.1. Pharmaceutical / Biotech Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Hospitals
      • 7.3.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Clinical Diagnostic Labs
      • 7.3.4.1. Clinical Diagnostic Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Others
      • 7.3.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Blood-based Biomarker for Parkinson's Disease Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Blood-based Biomarker for Parkinson's Disease Market Share, By Region, 2024 & 2033 (USD Million)
  • 8.3. Regional Outlook
  • 8.4. North America
    • 8.4.1. North America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. U.S. Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Canada Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Mexico Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. UK Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Germany Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. France Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Italy Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Spain Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Denmark Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Sweden Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory framework/ reimbursement structure
      • 8.5.9.3. Competitive scenario
      • 8.5.9.4. Norway Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Japan Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. China Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. India Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Australia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. South Korea Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Thailand Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Brazil Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Argentina Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. South Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. UAE Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory framework/ reimbursement structure
      • 8.8.5.3. Competitive scenario
      • 8.8.5.4. Kuwait Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. IDEXX Laboratories, Inc.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Abbott Laboratories
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. ACOBIOM
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Alseres Pharmaceuticals
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Banyan Biomarkers
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. DiaGenic ASA
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Johnson & Johnson
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Merck KGaA
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. QIAGEN
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
      • 9.3.10.5. Quanterix
      • 9.3.10.6. Participant's Overview
      • 9.3.10.7. Financial Performance
      • 9.3.10.8. Product Benchmarking
      • 9.3.10.9. Strategic Initiatives
      • 9.3.10.10. Thermo Fisher Scientific
      • 9.3.10.11. Participant's Overview
      • 9.3.10.12. Financial Performance
      • 9.3.10.13. Product Benchmarking
      • 9.3.10.14. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Product launch
    • 9.4.4. Others
  • 9.5. List of other key players

List of tables

  • Table 1 List of secondary sources
  • Table 2 Blood-based Biomarker For Parkinson's Disease Market, by region, 2021 - 2033 (USD Million)
  • Table 3 Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 4 Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 5 Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 Canada Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Europe Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 23 Germany Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 24 Germany Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 25 Germany Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 27 UK Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 28 UK Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 29 France Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker For Parkinson's Disease Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Italy Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Spain Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Denmark Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 39 Denmark Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 42 Sweden Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 45 Norway Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 China Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 51 China Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 52 China Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 55 Japan Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 56 India Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 57 India Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 59 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 60 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 61 South Korea Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 67 Thailand Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 68 Latin America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 69 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 73 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 75 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 76 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 78 MEA Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 79 MEA Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 82 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 83 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 88 UAE Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 89 UAE Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 92 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 94 Company Overview
  • Table 95 Product Benchmarking
  • Table 96 Financial Performance
  • Table 97 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Blood-based Biomarker For Parkinson's Disease Market revenue, 2021-2033 (USD Million)
  • Fig. 10 Blood-based Biomarker For Parkinson's Disease Market snapshot
  • Fig. 11 Blood-based Biomarker For Parkinson's Disease Market driver impact
  • Fig. 12 Blood-based Biomarker For Parkinson's Disease Market restraint impact
  • Fig. 13 Blood-based Biomarker For Parkinson's Disease biomarker key takeaways (USD Million)
  • Fig. 14 Blood-based Biomarker For Parkinson's Disease Market: biomarker movement analysis
  • Fig. 15 Protein biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 16 Inflammatory markers market, 2021 - 2033 (USD Million)
  • Fig. 17 Metabolic markers market, 2021 - 2033 (USD Million)
  • Fig. 18 Transcriptomic/miRNA market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Blood-based Biomarker For Parkinson's Disease technology key takeaways (USD Million)
  • Fig. 21 Blood-based Biomarker For Parkinson's Disease Market: technology movement analysis
  • Fig. 22 ELISA/Immunoassay market, 2021 - 2033 (USD Million)
  • Fig. 23 Multiplex platforms market, 2021 - 2033 (USD Million)
  • Fig. 24 NGS/qPCR (genetic) market, 2021 - 2033 (USD Million)
  • Fig. 25 Mass spectrometry market, 2021 - 2033 (USD Million)
  • Fig. 26 Others market, 2021 - 2033 (USD Million)
  • Fig. 27 Blood-based Biomarker For Parkinson's Disease Market by End Use key takeaways (USD Million)
  • Fig. 28 Blood-based Biomarker For Parkinson's Disease Market: by End Use movement analysis
  • Fig. 29 Academic/Research Labs market, 2021 - 2033 (USD Million)
  • Fig. 30 Pharmaceutical /Biotech market, 2021 - 2033 (USD Million)
  • Fig. 31 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 32 Clinical Diagnostic Labs market, 2021 - 2033 (USD Million)
  • Fig. 33 Others market, 2021 - 2033 (USD Million)
  • Fig. 34 Regional market place: Key takeaways
  • Fig. 35 Regional outlook, 2024 & 2033
  • Fig. 36 North America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 41 UK Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 43 France Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 45 Spain Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 51 China Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 52 India Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 54 South Korea Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 64 Market participant categorization